Clinical Trials Browser

Phase 1/2 × Sarcoma × Imatinib Mesylate × Clear all

NCT04138381 2023-03-27

SeliGIST

Phase 1/2 Unknown

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

NCT01275222 2021-06-25

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Phase 1/2 Completed

117 enrolled 18 charts

GastrointestinalSarcoma

Digestive System Neoplasms, Sarcoma, Stomach Neoplasms, Gastrointestinal Stromal Tumors

NCT01281865 2014-10-08

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

Phase 1/2 Completed

14 enrolled 7 charts

Sarcoma, Sarcoma, Synovial

NCT00006357 2012-09-24

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Phase 1/2 Completed

GastrointestinalGynecologicSarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Endometrial Neoplasms, Sarcoma, Endometrial Stromal, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Gastrointestinal Stromal Tumors, Histiocytoma, Malignant Fibrous